Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

The Lancet

Volumn 374, Issue 9683, 2009, Pages 56-64

  Priotto, Gerardo ^a   Kasparian, Serena ^a   Mutombo, Wilfried ^b   Ngouama, Daniel ^c   Ghorashian, Sara ^d   Arnold, Ute ^d   Ghabri, Salah ^a   Baudin, Elisabeth ^a   Buard, Vincent ^e   Kazadi Kyanza, Serge ^e   Ilunga, Médard ^b   Mutangala, Willy ^b   Pohlig, Gabriele ^f   Schmid, Caecilia ^f   Karunakara, Unni ^d   Torreele, Els ^g   Kande, Victor ^b  

^a EPICENTRE   (France)

^b Ministry of Health   (Democratic Republic Congo)

^c Ministry of Health   (Congo)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e MÉDECINS SANS FRONTIÈRES   (Belgium)

^f SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^g Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; NIFURTIMOX;

ABDOMINAL PAIN; ADULT; AFRICAN TRYPANOSOMIASIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; ATAXIA; BILIRUBIN BLOOD LEVEL; BODY FLUID; CLINICAL TRIAL; COMA; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; EXTRAVASATION; FEMALE; FOOD REGURGITATION; HALLUCINATION; HICCUP; HUMAN; HYPERTENSION; HYPOVOLEMIC SHOCK; INJECTION SITE REACTION; INNER EAR DISEASE; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SEIZURE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; TRYPANOSOMA; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 67649635323     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61117-X     Document Type: Article

References (30)

1. Simarro P.P., Jannin J., and Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next?. PLoS Med 5 (2008) e55
2. WHO. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. World Health Organ Tech Rep Ser 881 (1998) 1-114
3. Burri C., and Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 6 (2001) 412-420
4. Legros D., Evans S., Maiso F., Enyaru J.C., and Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93 (1999) 439-442
5. Stanghellini A., and Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 6 (2001) 330-334
6. Robays J., Nyamowala G., Sese C., et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14 (2008) 966-967
7. Moore A.C. Prospects for improving African trypanosomiasis chemotherapy. J Infect Dis 191 (2005) 1793-1795
8. Metcalf B.W., Bey P., Danzin C., Jung M.J., Casara P., and Vevert J.P. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogues. J Am Chem Soc 100 (1978) 2551-2553
9. Bacchi C.J., Nathan H.C., Hutner S.H., McCann P.P., and Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210 (1980) 332-334
10. Bacchi C.J., Garofalo J., Mockenhaupt D., et al. In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol 7 (1983) 209-225
11. Abeloff M.D., Slavik M., Luk G.D., et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine-an inhibitor of polyamine biosynthesis. J Clin Oncol 2 (1984) 124-130
12. Griffin C.A., Slavik M., Chien S.C., et al. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine. Invest New Drugs 5 (1987) 177-186
13. Pepin J., Khonde N., Maiso F., et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 78 (2000) 1284-1295
14. Janssens P.G., and De Muynck A. Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 57 (1977) 475-480
15. Moens F., De Wilde M., and Ngato K. Clinical trial of nifurtimox in human African trypanosomiasis. Ann Soc Belg Med Trop 64 (1984) 37-43 (in French).
16. Pepin J., Milord F., Meurice F., Ethier L., Loko L., and Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86 (1992) 254-256
17. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop 72 suppl 1 (1992) 39-51
18. Wegner D.H., and Rohwedder R.W. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 22 (1972) 1624-1635
19. Priotto G., Fogg C., Balasegaram M., et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1 (2006) e39
20. Checchi F., Piola P., Ayikoru H., Thomas F., Legros D., and Priotto G. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1 (2007) e64
21. Priotto G., Kasparian S., Ngouama D., et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 45 (2007) 1435-1442
22. Burri C., Nkunku S., Merolle A., Smith T., Blum J., and Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355 (2000) 1419-1425
23. Schmid C., Nkunku S., Merolle A., Vounatsou P., and Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364 (2004) 789-790
24. Bailey J.W., and Smith D.H. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 86 (1992) 630
25. WHO. Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis (2007), World Health Organization, Geneva. WHO/CDS/NTD/IDM/2007.1 http://www.who.int/neglected_diseases/mediacentre/Final%20Clinical_produ cts_for_trypanosomiasis%20November%2007.pdf (accessed June 9, 2009).
26. NCI-CTEP-NIH. Common toxicity criteria, version 2.0 (1999), National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, MD. http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/doc s/ctcv20_4-30-992.pdf (accessed June 16, 2009).
27. Blackwelder W.C. "Proving the null hypothesis" in clinical trials. Control Clin Trials 3 (1982) 345-353
28. Iten M., Mett H., Evans A., Enyaru J.C., Brun R., and Kaminsky R. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother 41 (1997) 1922-1925
29. Priotto G., Pinoges L., Fursa I.B., et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 336 (2008) 705-708
30. Schmid C., Richer M., Bilenge C.M., et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 191 (2005) 1922-1931